



## Curriculum Vitae

Personal  
information

Ferran Torres

Work  
experience

- 
1. Employer: Universitat Autònoma de Barcelona
    - Start date: 092021
    - End date: Cont
    - Position: Full time Associate Profesor, Biostatistics Unit, Medical School
    - Activities:
    - Country: Spain
  2. Employer: Hospital Clinic Barcelona
    - Start date: 012018
    - End date: 102021
    - Position: Consultant. Clinical Pharmacology Department
    - Activities:
    - Country: Spain
  3. Employer: Hospital Clinic Barcelona
    - Start date: 072007
    - End date:
    - Position: Scientific Director of the Medical Statistics Core Facility
    - Activities:
    - Country: Spain
  4. Employer: Universitat Autònoma de Barcelona
    - Start date: 091994
    - End date: 102021
    - Position: Part time Associate professor, Biostatistics Unit, Medical School
    - Activities:
    - Country: Spain
  5. Employer: Universitat Autònoma de Barcelona
    - Start date: 011993
    - End date: 081994
    - Position: Granted Fellowship
    - Activities:
    - Country: Spain
  6. Employer: Ministry of Health.
    - Start date: 121988
    - End date: 121992

- Position: Clinical Pharmacology medical speciality. Medical internal resident
- Activities:
- Country: Spain

7. Employer: Hospital Sant Pau Barcelona

- Start date: 011996
- End date: 012000
- Position: Responsible of Statistics at Clinical Pharmacology Department
- Activities:
- Country: Spain

## Education and training

---

1. Subject: Hospital Clínic. Universitat de Barcelona

- Start date: 091982
- End date: 061988
- Qualification: Medical doctor
- Organisation:
- Country: Spain

2. Subject: Hospital Vall Hebron. Barcelona

- Start date: 121988
- End date: 121992
- Qualification: Clinical Pharmacology medical speciality
- Organisation:
- Country: Spain

3. Subject: Universitat Autònoma de Barcelona

- Start date: 011993
- End date: 051998
- Qualification: PhD (Methodological and Statistical Issues of Sequential Clinical Trials)
- Organisation:
- Country: Spain

## Additional information

---

### Publications

More than 350 published papers in indexed scientific journals with a cumulated IF of >1700 (Q1:66%, Q2:21%, Q3:8%, Q4:5%), >20.000 citations, h-index=7  
<https://portalreerca.uab.cat/en/persons/ferran-torres>

The following list is restricted to the last 5 years of publication.

### 2024

Cabibbo G, Celsa C, Rimassa L, **Torres F**, Rimola J, Kloeckner R, Bruix J, Cammà C, Reig M. Navigating the Landscape of Liver Cancer Management: Designs in Clinical Trials and Clinical Practices. *J Hepatol.* 2024 Feb 1;S0168-8278(24)00095-3. doi: 10.1016/j.jhep.2024.01.018. Epub print. URL: <https://pubmed.ncbi.nlm.nih.gov/38307346>

Nicoară-Farcău O, Han G, Rudler M, Angrisani D, Monescillo A, **Torres F**, Casanovas G, Bosch J, Lv Y, Dunne PDJ, Hayes PC, Thabut D, Hernández-Gea V, García-Pagán JC; pre-emptive TIPS individual data metanalysis, International Variceal Bleeding Study and Baveno Cooperation groups. Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis. *Hepatology.* 2024 Mar 1; 63(3):635. doi: 10.1097/HEP.0000000000000613. Epub 2023 Oct 2. URL: <https://pubmed.ncbi.nlm.nih.gov/37782566>

Pesiou S, Barcelo R, Papazisis G, **Torres F**, Pontes C. Prevalence of use of on-label and off-label psychotropics in the Greek pediatric population. *Pharmacol.* 2024 Mar 14;15:1348887. doi: 10.3389/fphar.2024.1348887. URL: <https://pubmed.ncbi.nlm.nih.gov/38549664>

Ríos J, Sapena V, Mariño Z, Bruix J, Fornis X, Morros R, Reig M, **Torres F**, Pontes C. Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study. *Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study. Drugs Real World Outcomes.* 2024 Sep;11(3):389-401. doi: 10.1007/s40801-024-00437-y. Epub 2024 Jan 14. URL: <https://pubmed.ncbi.nlm.nih.gov/38874848>

"Sáez-Peñataro J, Calvo G, Bascuas J, Mosquera MM, Marcos MÁ, Egri N, **Torres F**. Association between Reactogenicity and Immunogenicity in a Vaccinated Cohort with Two mRNA SARS-CoV-2 Vaccines at a High-Complexity Reference Hospital: A Post Hoc Analysis on Immunology Aspects of a Prospective Cohort Study. *Vaccines (Basel).* 2024 Jun 17;12(6):10.3390/vaccines12060665. URL: <https://pubmed.ncbi.nlm.nih.gov/38932394>

Solé L, Lobo-Jarne T, Cabré-Romans JJ, González A, Fernandez L, Marruecos L, Guix M, Cuatrecasas M, López S, Bellosillo B, **Torres F**, Iglesias M, Espinosa L. Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients. *Biochim Biophys Acta Mol Cell Res.* 2024 Jan 1;2471(1):101166. doi: 10.1016/j.bbamcr.2024.119658. Epub ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/38216091>

Trujillo-Santos J, García-Escobar I, Salgado M, Araújo A, Martínez-de-Castro E, Molina R, Castellón-Rubio VE, Domènech P, Gallardo E, Colomé E, Benítez-Montañez JC, Porta R, Lobo-de-Mena M, Malheiro M, Font C, Brozos-Vázquez E, Garicano F, Sapena V, Costa AL, Albuquerque AC, CARTAGO Study Group. Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study. *Oncologist.* 2024 Dec 2;oyae334. doi: 10.1093/oncolo/oyae334. Epub ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/39673434>

Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, Eneanya N, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; **D:A:D cohort study**. Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration. *Clin Infect Dis.* 2024 Feb;79(5):1242-1257. doi: 10.1093/cid/ciae228. PMID: 38663013; PMCID: PMC11581700. URL: <https://pubmed.ncbi.nlm.nih.gov/38663013>

Vernooij RWM, Hockham C, Strippoli G, Green S, Hegbrant J, Davenport A, Barth C, Canaud B, Woodward M, Blankestijn PJ, Bots ML; COCKTAIL Scientific Committee; **HDF Pooling Project Investigators**. Haemodiafiltration versus haemodialysis for kidney failure: an individual patient data meta-analysis of randomised controlled trials. *Lancet.* 2024 Oct 25;S0140-6736(24)01859-2. doi: 10.1016/S0140-6736(24)01859-2. Epub ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/39489903>

Villanueva C, Sapena V, Lo GH, Seo YS, Shah HA, Singh V, Tripathi D, Schepke M, Gheorghe C, Bonilha DQ, Jutabha R, Wang HM, Rodrigues S, Azeiteiro J, Lee HA, Azam Z, Kumar P, Hayes PC, Sauerbruch T, Chen WC, Iacob S, Libera ED, Jensen DM, Alvarado E, **Torres F**, Bosch J; Baveno Cohort Consortium. Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data. *Aliment Pharmacol Ther.* 2024 Feb;59(3):306-321. doi: 10.1111/apt.17824. Epub 2024 Jan 18. URL: <https://pubmed.ncbi.nlm.nih.gov/38108646>

Yanagihara TK, Tepper JE, Moon AM, Barry A, Molla M, Seong J, **Torres F**, Apisarnthanarax S, Buckstein M, Cardenes H, Chang DT, Feng M, Hallemeier CL, Hawkins MA, Hoyer M, Iwata H, Jabbour SK, Kachnic L, Kharofa J, Kim TH, Kirichenko A, Koay EJ, Makishima H, Mases J, Munoz-Schuffenegger P, Owen D, Park HC, Saez J, Sanford NN, Scorsetti M, Smith GL, Wo JY, Yoon SM, Lawrence TS, Reig M, Dawson LA. Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus. *Pract Radiat Oncol.* 2024 Mar-Apr;14(2):134-145. doi: 10.1016/j.pro.2023.08.016. Epub 2024 Jan 19. PMID: 38244026. *Pract Radiat Oncol.* 2024 Mar-Apr;14(2):134-145. doi: 10.1016/j.pro.2023.08.016. Epub 2024 Jan 19. URL: <https://pubmed.ncbi.nlm.nih.gov/38244026>

## 2023

De Roij Van Zijdewijn CL, Rootjes PA, Nubé MJ, Bots ML, Canaud B, Blankestijn PJ, Van Ittersum FJ, Maas R, Morena M, Peters SA, Davenport A, Vernooij RW, Grooteman MP, Bots ML, Blankestijn PJ, Canaud B, Davenport A, Grooteman MP, Nubé MJ, Peters SA, Morena M, Maduell F, **Torres F**, Ok E, Asci G, Locatelli F, on behalf of the HDF Pooling Project investigators. Liver peridialytic blood pressure changes are related to mortality. *Nephrology Dialysis Transplantation* 2023;38(9):1992-2000. URL: <https://pubmed.ncbi.nlm.nih.gov/36496176>.

Elvira D, **Torres F**, Vives R, Puig G, Obach M, Gay D, Varón D, de Pando T, Tabernero J, Pontes C. Reporting reimbursement price decisions for hematologic drugs in Spain. *Front Public Health.* 2023 Oct 24;11:1265323. doi: 10.3389/fpubh.2023.1265323.

<https://pubmed.ncbi.nlm.nih.gov/37942255>.

Iavarone M, Nault JC, Cabibbo G, **Torres F**, Reig M. Indolent cancer and pattern of progression: Two missing parameters in trial design for hepatocellular carcinoma. *Hepatology*. 2023 Jul 3. doi: 10.1097/HEP.0000000000000527. Epub ahead of print. PMID: 37399245.. URL: <https://pubmed.ncbi.nlm.nih.gov/37399245>.

Juanola A, Ma AT, de Wit K, Gananandan K, Roux O, Zaccherini G, Jiménez C, Tonon M, Solé C, Villaseca C, Uschner FE, Graupera I, Pose E, Campion D, Beuers U, Mookerjee RP, Francoz C, Durand F, Vargas V, Piano S, Alonso S, Trebicka J, Laleman W, Asrani SK, Soriano G, Alessandri EA, Burriel M, Morales-Ruiz M, **Torres F**, Allegretti AS, Krag A, Caraceni P, Watson H, Abraldes JG, Solà E, Kamath PS, Hernaez R, Ginès P; LiverHope Consortium Investigators. . Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.. *Gut*. 2023 Oct 26;gutjnl-2023-329923. doi: 10.1136/gutjnl-2023-329923. Epub ahead of print. . URL: <https://pubmed.ncbi.nlm.nih.gov/37884354>.

Nicoară-Farcău O, Lozano JJ, Alonso C, Sidorova J, Villanueva C, Albillos A, Genescà J, Llop E, Calleja JL, Aracil C, Bañares R, Morillas R, Poca M, Peñas B, Augustin S, Tantău M, Thompson M, Perez-Campuzano V, Baiges A, Turon F, Hernandez-Ilizapalacio M, Abraldes JG, Tapias EA, **Torres F**, Bosch J, Garcia-Pagan JC; PreDesCI Study Investigators.. Metabolomics as a tool to predict the risk of decompensation or liver related death in patients with compensated cirrhosis. *Hepatology*. 2023 Jun 1;77(6):2052-2062. doi: 10.1097/HEP.0000000000000316. Epub ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/36811400>.

Ouchi D, Giner-Soriano M, Vilaplana-Carnerero C, Monfà R, **Torres F**, Morros R.. Longitudinal treatment patterns in patients recently diagnosed with type 2 diabetes mellitus in Catalonia. *Diabetes Res Clin Pract*. 2023 Aug;202:110777. doi: 10.1016/j.diabres.2023.110777. Epub 2023 Jun 15. URL: <https://pubmed.ncbi.nlm.nih.gov/37321303>.

Ouchi D, Vilaplana-Carnerero C, Monfà R, Giner-Soriano M, Garcia-Sangenís A, **Torres F**, Morros R. Impact of Second-Line Combination Treatment on Glycemic Control in Type 2 Diabetes Mellitus on Disease Control: A Population-Based Cohort Study. *Drugs Real World Outcomes*. 2023 May 9. doi: 10.1007/s40801-023-00370-9. Epub ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/37160557>.

Pesiou S, Barcelo R, Fradera M, **Torres F**, Pontes C. Utilisation of drugs for the treatment of psychiatric diseases in the pediatric population: focus on antidepressants. *Front Pharmacol*. 2023 Jun 16;14:1157135. doi: 10.3389/fphar.2023.1157135. eCollection 2023.. URL: <https://pubmed.ncbi.nlm.nih.gov/37397481>.

Pose E

Jiménez C, Zaccherini G, Campion D, Piano S, Uschner FE, de Wit K, Roux O, Gananandan K, Laleman W, Solé C, Alonso S, Cuyas B, Juanola A, Ma AT, Napoleone L, Gratacos J, Tonon M, Pompili E, Sánchez-Delgado J, Pérez M, Fabrellas N, Pich J, Martell C, Casanovas G, Domenech G, **Torres F**, Manuel V, Blasco V, Caraceni P, Alessandria C, Abraldes JG, Trebicka J, Beuers U, Francoz C, Mookerjee R, Bañares R, Soriano G, Hernaez R, Allegretti AS, Morales-Ruiz M, Serra M, Watson H, Abad-Saiz M, Kamath PS, Ginès P. Simvastatin plus Rifaximin to prevent ACLF in patients with decompensated cirrhosis. A randomised, double-blind, placebo-controlled phase-3 trial: the liverhope efficacy trial. *Journal of hepatology* 2023;78(Supplement 1):S10-511. URL: <https://pubmed.ncbi.nlm.nih.gov/>

Rowe IA, Villanueva C, Shearer JE, **Torres F**, Albillos A, Genescà J, Garcia-Pagan JC, Tripathi D, Hayes PC, Bosch J, Abraldes JG; PREDICI Investigators. Quantifying the benefit of non-selective beta-blockers in the prevention of hepatic decompensation: a Bayesian re-analysis of the PREDICI study. *Hepatology*. 2023 Mar 13. doi: 10.1097/HEP.0000000000000342. Online ahead of print.. URL: <https://pubmed.ncbi.nlm.nih.gov/36897269>.

Ruiz-García A, Pallarés-Carratalá V, Turégano-Yedro M, **Torres F**, Sapena V, Martín-Gorgojo A, Martín-Moreno JM. Vitamin D Supplementation in Patients with Liver Disease: Impact on Mortality and Cardiovascular Outcomes: Systematic Review and Meta-Analysis of 80 Randomized Clinical Trials. *Nutrients*. 2023 Apr 7;15(4):1028. doi: 10.3390/nu15081810. URL: <https://pubmed.ncbi.nlm.nih.gov/37111028>.

Villanueva C, **Torres F**, Tripathi D, Bosch J; Carvedilol-IPD-MA-group.. Reply to: "Carvedilol in patients with compensated cirrhosis: The ongoing definitive randomised trials over meta-analysis in patients with small varices". *J Hepatol*. 2023 Feb 25;S0168-8278(23)00114-9. doi: 10.1016/j.jhep.2023.02.011. Online ahead of print.. URL: <https://pubmed.ncbi.nlm.nih.gov/36848975>.

## 2022

Andreu A, Flores L, Molero J, Mestre C, Obach A, **Torres F**, Moizé V, Vidal J, Navinés R, Peri JM, Cañizares S. Patients Undergoing Bariatric Surgery: A Special Risk Group for Lifestyle, Emotional and Behavioral Adaptations During the COVID-19 Lockdown. Lessons from the First Wave. *Obesity Reviews*. 2022 Feb;24(2):441-449. doi: 10.1007/s11695-021-05792-1. URL: <https://pubmed.ncbi.nlm.nih.gov/34791617/>.

Carol M, Pérez-Guasch M, Solà E, Cervera M, Martínez S, Juanola A, Ma AT, Avitabile E, Napoleone L, Pose E, Graupera I, Honrubia M, Korenjak M, **Torres F**, Ginès P, Fabrellas N; LiverHope Consortium Investigators. . Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with poor quality of life. *PLoS One*. 2022 Apr 6;17(4):e0265153. doi: 10.1371/journal.pone.0265153. URL: <https://pubmed.ncbi.nlm.nih.gov/35385510/>.

Chamorro Á, **Torres F**. Intra-arterial Alteplase vs Placebo After Successful Thrombectomy and Functional Outcomes in Patients With Large Vessel Acute Ischemic Stroke-Reply. *JAMA*. 2022 Jun 28;327(24):2456. doi: 10.1001/jama.2022.7430. URL: <https://pubmed.ncbi.nlm.nih.gov/35763000/>.

Domingo P, Mateo MG, Villarroya J, Cereijo R, **Torres F**, Domingo JC, Campderrós L, Gallego-Escuredo JM, Gutierrez MDM, Mur I, Corbacho N, Villarroya F, Giralt M. Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living Receiving Combined Antiretroviral Therapy. *J Clin Med*. 2022 Jan 22;11(3):549. doi: 10.3390/jcm11030549. URL: <https://pubmed.ncbi.nlm.nih.gov/35763000/>.

Español-Rego M, Fernández-Martos C, Elez E, Foguet C, Pedrosa L, Rodríguez N, Ruiz-Casado A, Pineda E, Cid J, Cabezón R, Oliveres H, Lozano M, García-Criado A, Ayuso JR, Pagés M, Cuatrecasas M, **Torres F**, Thomson T, Cascante M, Benítez-Ribas D, Maurel J. . A Phase I-II multicenter Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1. *Cancer Immunol Immunother*. 2022 Sep 9. doi: 10.1007/s00262-022-03283-5. Epub ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/36083313/>.

Juanola A, Graupera I, Elia C, Piano S, Solé C, Carol M, Pérez-Guasch M, Bassegoda O, Escudé L, Rubio AB, Cervera M, Napoleone L, Avitabile S, Fabrellas N, Pose E, Morales-Ruiz M, Jiménez W, **Torres F**, Crespo G, Solà E, Ginès P. Urinary L-FABP is a promising prognostic biomarker of mortality in patients with decompensated cirrhosis. *J Hepatol*. 2022 Jan;76(1):107-114. doi: 10.1016/j.jhep.2021.08.031. Epub 2021 Sep 15. URL: <https://pubmed.ncbi.nlm.nih.gov/34530063/>.

Martin-Moreno JM, Alegre-Martinez A, Martin-Gorgojo V, Alfonso-Sanchez JL, **Torres F**, Pallares-Carratala V. Predictive Models for Forecasting Health Scenarios: Practical Experiences Applied during the First Wave of the COVID-19 Pandemic. *Int J Environ Res Public Health*. 2022 May 3;19(10):3111. doi: 10.3390/ijerph19095546. URL: <https://pubmed.ncbi.nlm.nih.gov/35564940/>.

Naranjo J, Furlano M, **Torres F**, Hernandez J, Pybus M, Ejarque L, Cordoba C, Guirado L, Ars E, Torra R. Comparative analysis of tools to predict disease progression in autosomal dominant polycystic kidney disease. *Clin Kidney J*. 2022 May; 15(5): 912–921. doi: 10.1093/ckj/sfab293

Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, **Torres F**, Bruix J, Reig M, Toso C. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. *Clin Gastroenterol Hepatol*. 2022 Feb;20(2):283-291. doi: 10.1016/j.cgh.2021.05.002. Epub 2021 May 28. URL: <https://pubmed.ncbi.nlm.nih.gov/33965578/>.

Ouchi D, Giner-Soriano M, Gómez-Lumbreras A, Vedia Urgell C, **Torres F**, Morros R. Automatic Estimation of the Most Likely Drug Combination in Health Records Using the Smooth Algorithm: Development and Validation Study. *JMIR Med Inform*. 2022 Nov 15;10(11):e37976. doi: 10.2196/37976

Renú A, Millán M, San Román L, Blasco J, Martí-Fàbregas J, Terceño M, Amaro S, Serena J, Urrea X, Laredo C, Barranco R, Camps-Renom P, Zarco A, Cardona P, Castaño C, Macho J, Cuadrado-Godía E, Vivas E, López-Rueda A, Guimaraens L, Ramos-Pachón A, Roquer J, Muchada M, Torralba J, Dávalos A, **Torres F**, Chamorro Á; CHOICE Investigators. . JAMA 2022 Mar 1;327(9):826-835. doi: 10.1001/jama.2022.1640. URL: <https://pubmed.ncbi.nlm.nih.gov/35143603/>.

Sáez-Peñataro J, **Torres F**, Bartra J, Bascuas J, Vilella A, Tortajada M, Quesada S, González E, López-Suñé E, Castells A, Serrano S, Camacho C, Calvo G; VigilVacCOVID Group. Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Hospital: Between-Vaccine and Between-Population Prospective Observational Study (VigilVacCOVID Study). . *BioDrugs*. 2022 Jun 28. doi: 10.1007/s12250-022-00543-9. Epub ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/35764768/>.

Sanduzzi-Zamparelli M, Mariño Z, Lens S, Sapena V, Iserte G, Pla A, Granel N, Bartres C, Llarch N, Vilana R, Nuñez I, Darnell A, Belmonte E, Garcia A, Díaz A, Muñoz-Martinez S, Ayuso C, Bianchi L, Fuster-Anglada C, Rimola J, Forner A, **Torres F**, Bruix J, Forns X, Reig M. Liver cancer risk reduction with curative-intent therapy in patients with advanced liver disease without non-characterized nodules. *J Hepatol*. 2022 Apr;76(4):874-882. doi: 10.1016/j.jhep.2021.11.010. URL: <https://pubmed.ncbi.nlm.nih.gov/34856322/>.

Sapena V, Enea M, **Torres F**, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoda H, Brillanti A, Degasperis E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Trevisani F, Cammà C, Bruix J, Cabibbo G, Reig M. . Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient analysis. *Gut*. 2022 Mar;71(3):593-604. doi: 10.1136/gutjnl-2020-323663. Epub 2021 Mar 19. URL: <https://pubmed.ncbi.nlm.nih.gov/33741640/>.

Sapena V, Iavarone M, Boix L, Facchetti F, Guarino M, Sanduzzi Zamparelli M, Granito A, Samper E, Scartozzi M, Corominas J, Marisi G, Díaz A, Gardini A, Gramantieri L, Lampertico P, Morisco F, **Torres F**, Bruix J, Reig M. Polymorphism AGT2 (rs4762) is involved in the development of decompensated liver events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib. *World J Hepatol*. 2022 Jul 27;14(7):1438-1447. doi: 10.4254/wjh.v14.i7.1438. URL: <https://pubmed.ncbi.nlm.nih.gov/36158918/>.

Solé L, Lobo-Jarne T, Álvarez-Villanueva D, Alonso-Marañón J, Guillén Y, Guix M, Sangrador I, Rozalén C, Vert A, Barbachano A, Lop J, Salido M, García-Romero R, Garrido M, González J, Martínez-Iniesta M, López-Arribillaga E, Salazar R, Montagut C, **Torres F**, Iglesias M, Celià-Terrassa

A, Villanueva A, Bigas A, Espinosa L. p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor survival. *Nat Commun.* 2022 May 23;13(1):2866. doi: 10.1038/s41467-022-30382-9. URL: <https://pubmed.ncbi.nlm.nih.gov/35606354/>.

van Kruijsdijk RCM, Vernooij RWM, Bots ML, Peters SAE, Dorresteijn JAN, Visseren FLJ, Blankestijn PJ, Debray TPA; **HDF Pooling Project Investigators**. Personalizing treatment in end-stage kidney disease: deciding between haemodiafiltration and haemodialysis based on individualized treatment effect. *Clin Kidney J.* 2022 Jun 20;15(10):1924-1931. doi: 10.1093/ckj/sfac153. URL: <https://pubmed.ncbi.nlm.nih.gov/36158156/>.

Villanueva C, **Torres F**, Sarin SK, Shah HA, Tripathi D, Brujats A, Rodrigues SG, Bhardwaj A, Azam Z, Hayes PC, Jindal A, Abid S, Alvarado E, et al. Carvedilol-IPD-MA-group, From the PREDESCI study (Ref. 7); From the study by Shah HA et al (Ref.16); From the study by Tripathi D et al (Ref.17); From the study by Bhardwaj A et al (Ref.15); Baveno Cooperation: an EASL Consortium. Carvedilol reduces the risk of decompensation and mortality with compensated cirrhosis in a competing-risk meta-analysis. *Hepatology.* 2022 May 31;S0168-8278(22)00336-1. doi: 10.1016/j.jhep.2022.05.001. URL: <https://pubmed.ncbi.nlm.nih.gov/35661713/>.

## 2021

Agusti A, **Torres F**, Faner R. Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19. *Lancet Respir Med.* 2021 Sep 9;S2213-2600(21)00171-5. doi: 10.1016/S2213-2600(21)00171-5. URL: <https://pubmed.ncbi.nlm.nih.gov/33844998/>.

Avendaño-Solá C, Ramos-Martínez A, Muñoz-Rubio E, Ruiz-Antorán B, Malo de Molina R, **Torres F**, Fernández-Cruz A, Calderón-Parra J, Payares-Díaz de Santiago A, Romera-Martínez I, Pintos I, Lora-Tamayo J, Mancheño-Losa M, Paciello ML, Martínez-González AL, Vidán-Estévez J, Nuñez-MJ, Saez-Serrano MI, Porras-Leal ML, Jarilla-Fernández MC, Villares P, de Oteyza JP, Ramos-Garrido A, Blanco L, Madrigal-Sánchez ME, Rubio-Velasco-Iglesias A, Paño-Pardo JR, Moreno-Chulilla JA, Muñiz-Díaz E, Casas-Flecha I, Pérez-Olmeda M, García-Pérez J, Alcamí J, Bueno JL, I ConPlas-19 Study Group. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. *Clin Infect Dis.* 2021 Oct 15;73(10):e12274. doi: 10.1093/cid/ciab274. URL: <https://pubmed.ncbi.nlm.nih.gov/34473652/>.

Avendaño-Solá C, Ramos-Martínez A, Muñoz-Rubio E, Ruiz-Antorán B, Malo de Molina R, **Torres F**, Fernández-Cruz A, Calderón-Parra J, Payares-Díaz de Santiago A, Romera-Martínez I, Pintos I, Lora-Tamayo J, Mancheño-Losa M, Paciello ML, Martínez-González AL, Vidán-Estévez J, Nuñez-MJ, Saez-Serrano MI, Porras-Leal ML, Jarilla-Fernández MC, Villares P, de Oteyza JP, Ramos-Garrido A, Blanco L, Madrigal-Sánchez ME, Rubio-Velasco-Iglesias A, Paño-Pardo JR, Moreno-Chulilla JA, Muñiz-Díaz E, Casas-Flecha I, Pérez-Olmeda M, García-Pérez J, Alcamí J, Bueno JL, I ConPlas-19 Study Group. *J Clin Invest.* 2021 Oct 15;131(20):e152740. doi: 10.1172/JCI152740. URL: <https://pubmed.ncbi.nlm.nih.gov/34473652/>.

Cabibbo G, Reig M, Celsa C, **Torres F**, Battaglia S, Enea M, Rizzo GEM, Petta S, Calvaruso V, Di Marco V, Craxì A, Singal AG, Bruix J, Cammà C. Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. *Liver Cancer.* 2021 Feb 23;11(1):75-84. doi: 10.1159/000520278. URL: <https://pubmed.ncbi.nlm.nih.gov/35222509/>.

Casals G, Andreu A, Barral Y, Ventosa S, Redondo M, **Torres F**, Ibarzábal A, Manau D, Carmona F, Vidal J, Flores L. Bariatric Surgery on Real-World Outcomes: the Impact According to the Diagnosis of Polycystic Ovarian Syndrome and Surgical Procedures. *Obes Surg.* 2021 Feb 24. doi: 10.1007/s11695-021-05297-x. Epub ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/33629226/>.

Chammartin F, Lodi S, Logan R, Ryom L, Mocroft A, Kirk O, d'Arminio Monforte A, Reiss P, Phillips A, El-Sadr W, Hatleberg CI, Pradier C, Bonetti M, De Wit S, Sabin C, Lundgren JD, Bucher HC; **D:A:D Study Group**. Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Late Initiation of Antiretroviral Therapy: A Multinational Prospective Cohort Study. *Ann Intern Med.* 2021 Jun;174(6):768-776. doi: 10.7326/M20-5226. Epub Mar 16. URL: <https://pubmed.ncbi.nlm.nih.gov/33721519/>.

Corominas J, Sapena V, Sanduzzi-Zamparelli M, Millán C, Samper E, Llarch N, Iserte G, **Torres F**, Da Fonseca LG, Muñoz-Martínez S, Forner A, Bruix J, Reig M. Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma (Basel). *Front Oncol.* 2021 Jan 23;13(3):426. doi: 10.3390/cancers13030426. URL: <https://pubmed.ncbi.nlm.nih.gov/33498698/>.

Diago-Sempere E, Bueno JL, Sancho-López A, Rubio EM, **Torres F**, de Molina RM, Fernández-Cruz A, de Diego IS, Velasco-Iglesias A, Payares-Díaz de Santiago A, Flecha IC, Avendaño-Solá C, Palomino RD, Ramos-Martínez A, Ruiz-Antorán B. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. *Trials.* 2021 Jan 20;22(1):118. doi: 10.1186/s13063-020-05011-9. URL: <https://pubmed.ncbi.nlm.nih.gov/33472681/>.

Díaz-González Á, Sapena V, Boix L, **Torres F**, Sanduzzi-Zamparelli M, Da Fonseca LG, Llarch N, Iserte G, Guedes C, Muñoz-Martínez S, Forner A, Belmonte E, Rimola J, Forner A, Ayuso C, Bruix J, Reig M. Early diarrhoea under sorafenib as a marker to consider the early migration to second-line therapy. *United European Gastroenterol J.* 2021 Jul;9(6):655-661. doi: 10.1002/ueg2.12111. Epub 2021 Jul 6. URL: <https://pubmed.ncbi.nlm.nih.gov/34228394/>.

Furlano M, Martínez V, Pybus M, Arce Y, Crespi J, Venegas MDP, Bullich G, Domingo A, Ayasreh N, Benito S, Lorente L, Ruíz P, Gonzalez VL, Alarcón-Cabello E, **Torres F**, Guirado L, Ars E, Torra R. Clinical and Genetic Features of Autosomal Dominant Alport Syndrome: A Cohort Study. *Am J Kidney Dis.* 2021 Jun 15;77(6):903-913. doi: 10.1053/j.ajkd.2021.04.011. URL: <https://pubmed.ncbi.nlm.nih.gov/34228394/>.

2021 Apr 7;S0272-6386(21)00505-9. doi: 10.1053/j.ajkd.2021.02.326. URL: <https://pubmed.ncbi.nlm.nih.gov/33838161/>.

González-Juanatey JR, Tamargo J, **Torres F**, Weisser B, Oudovenko N. Pharmacodynamic Study of the Cardiovascular Polypill. Is There Any Among the Monocomponents?. *Rev Esp Cardiol (Engl Ed)*. 2021 Jan;74(1):51-58. English, Spanish. doi: 10.1016/j.rec.2019.11.008. Epub 2020 Jan 1. URL: <https://pubmed.ncbi.nlm.nih.gov/31983653/>.

Gorgas MQ, **Torres F**, Vives R, Lopez-Rico I, Capella D, Pontes C. Effects of selective serotonin reuptake inhibitors and other antidepressant drugs on hip fracture: a case-control study in an elderly Mediterranean population. *Eur J Hosp Pharm*. 2021 Jan;28(1):28-32. doi: 10.1136/ejpharm-2019-00110. Epub 2019 May 20. URL: <https://pubmed.ncbi.nlm.nih.gov/33355280/>.

Mandorfer M, Turon F, Lens S, Baiges A, García-Criado Á, Darnell A, Belmonte E, Ferrusquía-Acosta J, Magaz M, Perez-Campuzano V, Olivas P, Casanovas G, **Torres F**, Mariño Z, Fornis X, Hernández-Gea V, García-Pagán JC. Risk of non-tumoural portal vein thrombosis in patients with HC cirrhosis after sustained virological response. *Liver Int*. 2021 Jul 9. doi: 10.1111/liv.15009. Online ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/34242479/>.

Naranjo J, Furlano M, **Torres F**, Hernandez J, Pybus M, Ejarque L, Cordoba C, Guirado L, Ars E, Torra R. Comparative analysis of tools to predict disease progression in autosomal dominant polycystic kidney disease. *Clin Kidney J*. 2021 Dec 28;15(5):912-921. doi: 10.1093/ckj/sfab292. URL: <https://pubmed.ncbi.nlm.nih.gov/35498884/>.

Nicoară-Farcău O, Han G, Rudler M, Angrisani D, Monescillo A, **Torres F**, Casanovas G, Bosch J, Lv Y, Thabut D, Fan D, Hernández-Gea V, García-Pagán JC; Preemptive TIPS Individual Data Metanalysis, International Variceal Bleeding Study and Baveno Cooperation Study groups. Effectiveness of Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. *Gastroenterology*. 2021 Jan;160(1):193-205.e10. doi: 10.1053/j.gastro.2020.09.026. Epub 2020 Sep 24. URL: <https://pubmed.ncbi.nlm.nih.gov/32980111/>.

Ortiz-Maldonado V, Rives S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, Baumann T, Cid J, Garcia-Rey E, Llanos C, Torrens M, Villamor N, Giné E, Díaz-Beyá M, Guardia L, Montoro M, Català A, Faura A, González EA, Español-Rego M, Klein-González N, Alsina L, Castro I, Fernández S, Ramos F, Suñé G, Perpiñá U, Canals JM, Lozano M, Trias E, Scalise A, Varea S, Sáez-Peñataro J, **Torres F**, Calvo G, Esteve J, Urbán A, Juan M, Delgado J. CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19 + Relapsed/Refractory Malignancies. *Ann Oncol*. 2021 Feb 3;29(2):636-644. doi: 10.1016/j.ymthe.2020.09.027. Epub 2020 Sep 20. URL: <https://pubmed.ncbi.nlm.nih.gov/33010231/>.

Petoumenos K, Kuwanda L, Ryom L, Mocroft A, Reiss P, De Wit S, Pradier C, Bonnet F, Phillips A, Hatleberg CI, d'Arminio Monforte A, Weber R, Lundgren J, Law MG; **D:A:D Study Group**. Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study. *J Acquir Immune Defic Syndr*. 2021 Apr 15;86(5):579-586. doi: 10.1097/QAI.0000000000002100. URL: <https://pubmed.ncbi.nlm.nih.gov/33351531/>.

Renú A, Blasco J, Millán M, Martí-Fàbregas J, Cardona P, Oleaga L, Macho J, Molina C, Roquer J, Amaro S, Dávalos A, Zarco F, Laredo C, Torrens M, Guimaraens L, Barranco R, Castaño C, Vivas E, Ramos A, López-Rueda A, Urrea X, Muchada M, Cuadrado-Godía E, Camps-Renom P, Román LS, Rodríguez EC, Jovin T, **Torres F**, Chamorro Á; CHOICE Investigators. The Chemical Optimization of Cerebral Embolectomy trial: Study protocol. *Int J Stroke*. 2021 Jan;16(1):110-116. doi: 10.1177/1747493019895656. Epub 2019 Dec 18. URL: <https://pubmed.ncbi.nlm.nih.gov/31852410/>.

Rimola J, Da Fonseca LG, Sapena V, Perelló C, Guerrero A, Simó MT, Pons M, De La Torre-Aláez M, Márquez L, Calleja JL, Lledó JL, Varela M, Muga S, Sangro B, Matilla A, **Torres F**, Ayuso C, Bruix J, Reig M. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter study of real-life practice. *Eur J Radiol*. 2021 Feb;135:109484. doi: 10.1016/j.ejrad.2020.109484. Epub 2020 Dec 17. URL: <https://pubmed.ncbi.nlm.nih.gov/33383399/>.

Rodríguez A, Esposito F, Oliveres H, **Torres F**, Maurel J. Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale of the Same Coin, to Grade Recommendations for Drug Approval?. *J Clin Med*. 2021 Feb 13;10(4):746. doi: 10.3390/jcm10040746. PMID: 33668473. PMC7918206. URL: <https://pubmed.ncbi.nlm.nih.gov/33668473/>.

Rudilosso S, Ríos J, Rodríguez A, Gomis M, Vera V, Gómez-Choco M, Renú A, Matos N, Llull L, Purroy F, Amaro S, Terceño M, Obach V, Sereno E, Fàbregas J, Cardona P, Molina C, Rodríguez-Campello A, Cánovas D, Krupinski J, Ustrell X, **Torres F**, Román LS, Salvat-Plana M, Jiménez-Fàbregas E, Catena E, Colom C, Cocho D, Baiges J, Aragones JM, Diaz G, Costa X, Almendros MC, Rybyebe M, Barceló M, Carrión D, López MN, de la Ossa NP, Urrea X, Chamorro Á; Catalan Stroke Code and Reperfusion (Cat-SCR) Consortium. Effectiveness of Thrombectomy in Stroke Acute Ischemic Stroke Baseline Prognostic Factors: Inverse Probability of Treatment Weighting Analysis of a Population-Based Registry. *Stroke*. 2021 Sep;52(9):1611-1619. doi: 10.1161/STROKEAHA.121.340111. Epub 2021 Aug 11. URL: <https://pubmed.ncbi.nlm.nih.gov/34011111/>.

Rudilosso S, Ríos J, Rodríguez A, Gomis M, Vera V, Gómez-Choco M, Renú A, Matos N, Llull L, Purroy F, Amaro S, Terceño M, Obach V, Sereno E, Fàbregas J, Cardona P, Molina C, Rodríguez-Campello A, Cánovas D, Krupinski J, Ustrell X, **Torres F**, Román LS, Salvat-Plana M, Jiménez-Fàbregas E, Catena E, Colom C, Cocho D, Baiges J, Aragones JM, Diaz G, Costa X, Almendros MC, Rybyebe M, Barceló M, Carrión D, López MN, de la Ossa NP, Urrea X, Chamorro Á; Catalan Stroke Code and Reperfusion (Cat-SCR) Consortium. J Stroke. 2021 Sep;23(3):401-409. doi: 10.1161/STROKEAHA.121.340111. Epub 2021 Aug 11. URL: <https://pubmed.ncbi.nlm.nih.gov/34011111/>.

10.5853/jos.2021.00962. Epub 2021 Sep 30. URL: <https://pubmed.ncbi.nlm.nih.gov/34649384/>.

Ruiz-Antorán B, Sancho-López A, **Torres F**, Fernández-Cruz A; TOCICOV study group. A Response to: Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort. *Infect Dis T* Sep;10(3):1811-1813. doi: 10.1007/s40121-021-00444-4. Epub 2021 Apr 29. URL: <https://pubmed.ncbi.nlm.nih.gov/33928532/>.

Ruiz-Antorán B, Sancho-López A, **Torres F**, Moreno-Torres V, de Pablo-López I, García-López P, Abad-Santos F, Rosso-Fernández CM, Aldean Montané E, Aparicio-Hernández RM, Llop-Rius R, Pedrós C, Gijón P, Hernández-Carballo C, Pedrosa-Martínez MJ, Rodríguez-Jiménez C, Prada-R Cabrera-García L, Aguilar-García JA, Sanjuan-Jimenez R, Ortiz-Barraza EI, Sánchez-Chica E, Fernández-Cruz A; TOCICOV-study group. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study. *Infect Dis T* Mar;10(1):347-362. doi: 10.1007/s40121-020-00373-8. Epub 2020 Dec 6. URL: <https://pubmed.ncbi.nlm.nih.gov/33280066/>.

Solà E, Pose E, Campion D, Piano S, Roux O, Simon-Talero M, Uschner F, de Wit K, Zaccherini G, Alessandria C, Beuers U, Caraceni P, Francoz C, RP, Trebicka J, Vargas V, Serra M, **Torres F**, Montagnese S, Krag A, Hernaez R, Korenjak M, Watson H, Abraldes JG, Kamath PS, Ginès P; Consortium Investigators. Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. *Hepatol*. 2021 Jan;74(1):200-219. doi: 10.1016/j.jhep.2020.08.009. URL: <https://pubmed.ncbi.nlm.nih.gov/32896580/>.

Vernooij RWM, Law W, Peters SAE, Canaud B, Davenport A, Grooteman MPC, Kircelli F, Locatelli F, Maduell F, Morena M, Nubé MJ, Ok E, Woodward M, Blankestijn PJ, Bots ML. **HDF Pooling project investigators**. The probability of receiving a kidney transplantation in end-stage kidney patients who are treated with haemodiafiltration or haemodialysis: a pooled individual participant data from four randomised controlled trials. *BMJ* 2021 Feb 25;22(1):70. doi: 10.1186/s12882-021-02265-6. URL: <https://pubmed.ncbi.nlm.nih.gov/33632160/>.

Villanueva C, Albillos A, Genesà J, Garcia-Pagan JC, Brujats A, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Alvarado E, **Torres F**, Bosch J; PreDesCI Study Investigators. Bacterial infections adversely influence the risk of decompensation and survival in cirrhosis. *J Hepatol*. 2021 Sep;75(3):589-599. doi: 10.1016/j.jhep.2021.04.022. Epub 2021 Apr 24. URL: <https://pubmed.ncbi.nlm.nih.gov/33905794/>.

## 2020

Alvarado-Tapias E, Ardevol A, Garcia-Guix M, Montañés R, Pavel O, Cuyas B, Graupera I, Brujats A, Vilades D, Colomo A, Poca M, Torras X, Concepción M, Aracil C, **Torres F**, Villanueva C. Short-term hemodynamic effects of  $\beta$ -blockers influence survival of patients with decompensated cirrhosis. *Hepatol*. 2020 Apr 13;S0168-8278(20)30211-7. doi: 10.1016/j.jhep.2020.03.048. Online ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/322987>.

Correll CU, Litman RE, Filts Y, Llaudó J, Naber D, **Torres F**, Martínez J. Efficacy and safety of once-monthly Risperidone ISM® in schizophrenia with an acute exacerbation. *NPJ Schizophr*. 2020 Nov 25;6(1):37. doi: 10.1038/s41537-020-00127-y. URL: <https://pubmed.ncbi.nlm.nih.gov/33239746/>.

Cucchiari D, Ríos J, Molina-Andujar A, Montagud-Marrahi E, Revuelta I, Ventura-Aguar P, Piñeiro GJ, De Sousa-Amorim E, Esforzado N, Torregrosa JV, Ugalde-Altamirano J, Ricart MJ, Rovira J, **Torres F**, Solè M, Campistol JM, Diekmann F, Oppenheimer F. Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice. *J Nephrol*. 2020 Jun;33(3):601-610. doi: 10.1007/s40620-019-00675-2. Epub 2019 Dec 18. URL: <https://pubmed.ncbi.nlm.nih.gov/31853792/>.

Díaz-González Á, Sapena V, Boix L, Brunet M, **Torres F**, LLarch N, Samper E, Millán O, Corominas J, Iserete G, Sanduzzi-Zamparelli M, da Figueiredo Darnell A, Belmonte E, Forner A, Ayuso C, Bruix J, Reig M. Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma. Implications for combination trials. *Liver Int*. 2020 Oct;40(10):2476-2488. doi: 10.1111/liv.14587. Epub 2020 Jul 21. URL: <https://pubmed.ncbi.nlm.nih.gov/33021346/>.

Diez AIG, Fuster D, Morata L, **Torres F**, Garcia R, Poggio D, Sotes S, Del Amo M, Isern-Kebeschull J, Pomes J, Soriano A, Brugnara L, Tomas X. Comparison of the diagnostic accuracy of diffusion-weighted and dynamic contrast-enhanced MRI with 18F-FDG PET/CT to differentiate osteomyelitis from Charcot osteoarthropathy in diabetic foot. *Eur J Radiol*. 2020 Sep 21;132:109299. doi: 10.1016/j.ejrad.2020.109299. Online ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/33032207/>.

Gil-López F, Boget T, Manzanares I, Donaire A, Conde-Blanco E, Baillés E, Pintor L, Setoain X, Bargalló N, Navarro J, Casanova J, Valls J, Roldán F, Casanovas G, Domenech G, **Torres F**, Carreño M. External trigeminal nerve stimulation for drug resistant epilepsy: A randomized controlled trial. *Brain* 2020 Jun 10;13(5):1245-1253. doi: 10.1016/j.brs.2020.06.005. Online ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/32534250/>.

Hollanda A, Lecube A, Rubio MA, Sánchez E, Vilarrasa N, Oliva JG, Fernández-Soto ML, Salas-Salvadó J, Ballesteros-Pomar MD, Ciudín A, **Torres F**, C, Morales MJ, Valdés S, Pellitero S, Miñambres I, Masmiquel L, Goday A, Suarez L, Flores L, Bueno M, Caixàs A, Bretón I, Cámara R, Olbeyra R, José de la Cruz M, Simó-Servat A, Pereyra-García FM, López-Mezquita ET, Gils A, Fidilio E, Bandrés O, Martínez Á, Abuín J, Marques-Pamies M, Artega M, Castañer O, Goñi F, Arrizabalaga C, Botana MA, Calañas A, Rebollo Á. New Metrics to Assess Type 2 Diabetes After Bariatric Surgery: T

Within-Remission Range". J Clin Med 2020 Apr 9;9(4):E1070. URL: <https://pubmed.ncbi.nlm.nih.gov/32283783/>.

Molero J, Olbeyra R, Vidal J, **Torres F**, Cañizares S, Andreu A, Ibarzabal A, Jiménez A, de Hollanda A, Moizé V, Flores L. A Propensity Score Cohort Study on the Long-Term Safety and Efficacy of Sleeve Gastrectomy in Patients Older Than Age 60. J Obes. 2020 Jul 31;2020:8783260. doi: 10.1155/2020/8783260. eCollection 2020. URL: <https://pubmed.ncbi.nlm.nih.gov/32802499/>.

Pose E, Napoleone L, Amin A, Campion D, Jimenez C, Piano S, Roux O, Uschner FE, de Wit K, Zaccherini G, Alessandria C, Angeli P, Bernardi M, Caraceni P, Durand F, Mookerjee RP, Trebicka J, Vargas V, Andrade RJ, Carol M, Pich J, Ferrero J, Domenech G, Llopis M, **Torres F**, Kamath PS, JG, Solà E, Ginès P. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):31-41. doi: 10.1016/S2468-1253(19)30320-6. Epub 2019 Oct 17. URL: <https://pubmed.ncbi.nlm.nih.gov/31607677/>.

Riquelme F, Muñoz C, Ausania F, Hessheimer AJ, **Torres F**, Calatayud D, Sandomenico R, García Pérez R, Ferrer J, Fuster J, García-Valdecasas JC, et al. Laparoscopic versus open hemihepatectomy: comprehensive comparison of complications and costs at 90 days using a propensity method. Updates Surg. 2020 Jul 30. doi: 10.1007/s13304-020-00854-y. Online ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/32734578/>.

Rodríguez-Tajes S, Pocurull A, Castillo J, Casanova G, Vega L, Lens S, Mariño Z, Londoño MC, Forner A, **Torres F**, Forns X. Hepatitis C-related cirrhosis may be a marginal cause of hospital admissions by 2025. J Hepatol. 2020 Jul 19:S0168-8278(20)30472-4. doi: 10.1016/j.jhep.2020.07.018. Online ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/32697948/>.

Rudilosso S, Laredo C, Vera V, Vargas M, Renú A, Llull L, Obach V, Amaro S, Urra X, **Torres F**, Jiménez-Fàbrega FX, Chamorro Á. Acute Stroke Risk in the Era of COVID-19: Experience at a Comprehensive Stroke Center in Barcelona. Stroke. 2020 May 22;51(5):1203-1208. doi: 10.1161/STROKEAHA.120.030329. Epub ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/32438895/>.

Ryom L, Lundgren JD, Reiss P, Ross M, Kirk O, Fux CA, Morlat P, Fontas E, Smith C, De Wit S, d'Arminio Monforte A, El Sadr W, Hatleberg C, et al. Sabin C, Law M, Mocroft A; D:A:D Study Group. The impact of immunosuppression on chronic kidney disease in people living with HIV; the D:A:D Study. Infect Dis. 2020 Jul 8;jiaa396. doi: 10.1093/infdis/jiaa396. Online ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/32640015/>.

Sapena V, Rios J, **Torres F**, Mariño Z, Forns X, Bruix J, Reig M. Reply to: "Response to Mariño et al. J Hep 2019 Study: The reported 'clear cut time' between interferon-free treatment and HCC' is anything but clear cut". J Hepatol 2020 May;72(5):1036-1037. doi: 10.1016/j.jhep.2019.12.003. Epub 2020 May 13. URL: <https://pubmed.ncbi.nlm.nih.gov/31843648/>.

Trebicka J, Gu W, Ibáñez-Samaniego L, Hernández-Gea V, Pitarch C, Garcia E, Procopet B, Giráldez Á, Amitrano L, Villanueva C, Thabut D, Silva P, Martínez J, Genescà J, Bureau C, Llop E, Laleman W, Palazon JM, Castellote J, Rodrigues S, Gluud L, Ferreira CN, Barcelo R, Cañete N, Rodríguez-Lizasoain J, Ferlitsch A, Mundi JL, Gronbaek H, Hernández-Guerra M, Sassatelli R, Dell'Era A, Senzolo M, Abraldes JG, Romero-Gómez M, Zipprich A, Casas M, et al. H, Primignani M, Weiss E, Catalina MV, Erasmus HP, Uschner FE, Schulz M, Brol MJ, Praktijnjo M, Chang J, Krag A, Nevens F, Calleja JL, et al. Conejo I, Albillos A, Rudler M, Alvarado E, Guardascione MA, Tantau M, Bosch J, **Torres F**, Pavesi M, Garcia-Pagán JC, Jansen C, Bañares R; International Variceal Bleeding Observational Study Group and Baveno Cooperation. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive beta-blockade. J Hepatol. 2020 Apr 24:S0168-8278(20)30236-1. doi: 10.1016/j.jhep.2020.04.024. Online ahead of print. URL: <https://pubmed.ncbi.nlm.nih.gov/32339444/>.

## Projects

### Scientific Projects.

**3 European projects:** (1) Principal investigator of a WP for the FP7 project on rare diseases *Advances in Small Trials dEsign for Rare Diseases Innovation and eXcellence* (ASTERIX). Period: 2014-2018. Code: FP7-HEALTH-2013-INNOVATION-1, Grant-Agreement No. 603160. Budget: 2,999,881€ (WP: 512,442€). UAB (2) Principal Investigator of a WP of a H2020 project: *AI supported picture archiving and communication system for large bowel camera capsule endoscopy* (AICE). Period: 2022-2026. Code: HEU-101057400-AICE. Budget: 4,650,797€ (WP: 3,150,000€). UAB. (3) Principal Investigator of a WP of a IHI project: *A Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease and Enable Personalized Therapy* (LIVERAIM). Period: 2024-2030. Code: JU-IHI-101132901-LIVERAIM. Budget: 13,854,593€ (WP: 7,500,000€). UAB.

**12 National projects:** Co-investigator in 11 ISCiii funded projects, overall budget 2,798,051€ (others than research networks SCReN 1,600,000€ for the latter 2,694,535€), 1 funded by the *Generalitat Catalunya* (18,000eur).

### Research experience.

Around 30 years' experience in the design and analysis of clinical trials and other studies in the hospital (Vall d'Hebron, Sant Pau, CIBER) and university (UAB) settings (1992-).

## Memberships

**Scientific regulatory experience.** Medical and statistical consultant to the Spanish Medicines Agency (AEMPS, 1999-); CAMH (Comitè Assessor de la Medicació Hospitalària) Board of the Hospital Medication, *Consell Assessor de la Medicació Hospitalària*, (full member: 2017-2024; expert member 2024-co

CatSalut (Catalan Health Service); member of the Scientific Advice Working Party (SAWP, 2008-2018 and 2020-2021) and observer of the Biostatistics Working Party (BSWP, 2017-, full member 2009-2017), European Specialised Expert Community member (ESECC) in the Methodology domain (Biostatistics) (2023-), groups at the European Medicines Agency (EMA).

**Scientific journals activities.** Associate editor of the *Trials Journal* (2015-2018); Statistical reviewer for; Statistical Advisory Board of *PlosOne*; Peer reviewer for a number of scientific journals (*Lancet Gastroenterology & Hepatology*, *Journal of Hepatology*, *Journal of Biopharmaceutical Statistics*, *Clinical Rheumatology*, *Trials*, *European Journal of Clinical Pharmacology*, *Medicina Clínica*, *Archivos de Bronconeumología*, etc.)

Other  
Relevant  
Information

ORCID: 0000-0002-7355-7913 => <http://orcid.org/0000-0002-7355-7913>; UAB: <https://portalrecerca.uab.cat/en/persons/ferran-torres>; SCOPUS: 7102336718 => <http://www.scopus.com/authid/detail.url?authorId=7102336718>; Portal of Catalonia: <https://portalrecerca.csuc.cat/orcid/0000-0002-7355-7913>